UK pharma major GSK (LSE: GSK) today reported first quarter 2024 financial results, showing that total sales were £7.4 billion ($9.26 billion) +10% and +13% ex COVID revenues.
Pre-tax profit, however, weakened 29% to £1.36 billion from £1.91 billion. Earnings per share were 43.1 pence compared to 36.8 pence a year ago.
GSK’s shares were up 2.0% to 1,706.00 pence in London this morning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze